A recent social media post by a prominent physician, Adam Gaffney, MD, a pulmonary and critical care doctor at Cambridge Health Alliance and Assistant Professor at Harvard Medical School, has sparked significant controversy and a robust debate within the chronic illness community. Dr. Gaffney’s assertion regarding the "over-diagnosis / misdiagnosis / self-diagnosis" of several complex, often misunderstood conditions—Ehlers-Danlos Syndromes (EDS), Mast Cell Activation Syndrome (MCAS), Postural Orthostatic Tachycardia Syndrome (POTS), and Lyme disease—drew immediate and widespread criticism from patients and advocates alike, highlighting persistent frustrations with diagnostic delays and medical skepticism.
The Catalyst: A Controversial Social Media Post
The controversy began when Dr. Gaffney posted on X (formerly Twitter): "Over-diagnosis / misdiagnosis / self-diagnosis of EDS, MCAS, POTS & Lyme is a real problem, and it would appear that there is little appetite by medical professionals to discuss this issue publicly." This statement, originating from a physician affiliated with prestigious institutions, quickly circulated, triggering a wave of responses from individuals living with these conditions. Many interpreted his remarks as dismissive of patient experiences and contributing to the very diagnostic challenges they face. In the wake of intense backlash, Dr. Gaffney subsequently made his entire X account private, effectively removing the original post from public view.
For clarity, the conditions mentioned are:
- Ehlers-Danlos Syndromes (EDS): A group of inherited connective tissue disorders primarily affecting the skin, joints, and blood vessel walls, leading to hypermobility, chronic pain, and various systemic issues. Hypermobile EDS (hEDS) is the most common type.
- Mast Cell Activation Syndrome (MCAS): A condition characterized by episodes of severe allergic symptoms, including hives, swelling, low blood pressure, difficulty breathing, and gastrointestinal issues, due to inappropriate activation and release of mediators from mast cells.
- Postural Orthostatic Tachycardia Syndrome (POTS): A disorder of the autonomic nervous system, characterized by an abnormal increase in heart rate that occurs when a person stands up, leading to symptoms like dizziness, lightheadedness, fatigue, and brain fog.
- Lyme Disease: A bacterial infection transmitted by ticks, which can lead to a range of symptoms affecting the skin, joints, heart, and nervous system if left untreated.
Immediate Reactions and Patient Perspectives
The reaction from the chronic illness community was swift and largely condemnatory. Patients and advocates expressed profound disappointment and anger, arguing that such statements exacerbate the already difficult journey to diagnosis and care for these conditions.
Lorelei Lee (@MissLoreleiLee) articulated a common sentiment, writing: "This is disgusting to say at a time when so many sick people are suffering because of the constant dismissal by doctors undertrained in these types of illness, overworked by a dysfunctional healthcare system, & seeing increased numbers in the wake of a debilitating pandemic." This highlights the intersection of medical gaslighting, systemic healthcare issues, and the rising prevalence of chronic conditions, particularly in the post-pandemic era.
Another user, Barry Hunt (@BarryHunt008), underscored the necessity of patient self-advocacy in a system that often fails to recognize their suffering: "Dear Adam, When medicine takes a decade to name what’s destroying your life And calls you hysterical in the interim ‘Self-diagnosis’ isn’t the problem It’s the solution." This perspective resonates with many who report years of being dismissed, misdiagnosed, or told their symptoms are psychosomatic before finally finding a correct diagnosis, often through their own research and community support.
The Reality of Underdiagnosis: A Data-Driven Overview
Contrary to the suggestion of overdiagnosis, extensive research and patient experiences consistently point to significant diagnostic delays and underdiagnosis for EDS, MCAS, POTS, and Lyme disease. These conditions are complex, multi-systemic, and often present with a wide array of non-specific symptoms, making them challenging for clinicians unfamiliar with their nuances.
Ehlers-Danlos Syndromes (EDS):
A 2025 study, a retrospective chart review, examining 429 patients eventually clinically diagnosed with hypermobile EDS (hEDS), revealed that 405 (94.4%) experienced misdiagnosis in at least one of five evaluated categories. This included being told their symptoms were psychosomatic, fabricated, or indicative of Munchausen syndrome. The average diagnostic delay for EDS is often cited as 10-12 years. The Ehlers-Danlos Society, a leading patient advocacy organization, continuously emphasizes the need for increased medical education to improve early and accurate diagnosis. Prevalence estimates for all types of EDS vary, but hEDS alone is thought to affect at least 1 in 5,000 people, though many experts believe this is an underestimate due to diagnostic challenges. The diagnostic criteria for hEDS, updated in 2017, require a thorough clinical assessment, including the Beighton score for hypermobility and careful evaluation of systemic manifestations.
Postural Orthostatic Tachycardia Syndrome (POTS):
Dysautonomia International, a non-profit organization dedicated to advocacy for dysautonomia patients, reports that it takes, on average, nearly six years for a patient to receive a correct POTS diagnosis. This delay is particularly concerning given that POTS affects an estimated 1 to 3 million Americans, predominantly women. The diagnostic process typically involves a tilt table test or active stand test, yet many primary care physicians and even some specialists may not be familiar with the condition or its diagnostic protocols. The COVID-19 pandemic has further amplified the urgency for better POTS recognition, as a significant percentage of individuals experiencing "long COVID" develop new-onset dysautonomia, including POTS. Studies have shown that up to 15% of long COVID patients exhibit POTS-like symptoms, indicating a growing need for medical professionals to adjust their diagnostic awareness and capacity.
Mast Cell Activation Syndrome (MCAS):
The Mayo Clinic acknowledges the significant diagnostic difficulties associated with MCAS. Due to its protean manifestations—symptoms can mimic allergies, autoimmune diseases, and various other conditions—patients often endure "lengthy diagnostic delays while seeing various specialists to try to find answers." MCAS is characterized by episodic symptoms affecting multiple organ systems, including dermatological (hives, flushing), gastrointestinal (abdominal pain, diarrhea), cardiovascular (tachycardia, hypotension), and neurological (headache, brain fog). The diagnosis relies on clinical symptoms, elevated mast cell mediators (like tryptase or histamine metabolites) during flares, and response to mast cell-stabilizing medications. The transient nature of mediator elevation and the complexity of testing contribute to misdiagnosis and underdiagnosis. Estimates for MCAS prevalence vary widely, from 1-17% of the population, underscoring the lack of clear epidemiological data due to diagnostic challenges.
Lyme Disease:
Johns Hopkins Medicine, a renowned institution for Lyme research and treatment, states that "many cases of Lyme disease are initially misdiagnosed because early symptoms of fever, severe fatigue, and achiness are also common in many other illnesses." The diagnostic landscape for Lyme disease is further complicated by challenges in serological testing, particularly in early stages or for those with chronic symptoms, and the controversy surrounding "chronic Lyme disease." The Centers for Disease Control and Prevention (CDC) estimates that approximately 476,000 Americans are diagnosed and treated for Lyme disease each year, a substantial figure that suggests its significant public health impact. Despite this, patients often report delays in diagnosis and treatment, leading to more severe and persistent symptoms.
Broader Context: Gender Bias, Patient Advocacy, and Medical Education
The contentious nature of Dr. Gaffney’s remarks also highlights several systemic issues within medicine:
Historical and Ongoing Gender Bias: Many of the conditions listed—EDS, MCAS, and POTS—disproportionately affect women. This demographic overlap is critical in understanding the patient backlash. Historically, women’s pain and symptoms have been systematically dismissed as psychological or "hysterical," leading to delayed diagnoses and inadequate treatment. Research consistently shows that women wait longer for diagnoses, receive less aggressive pain management, and are more likely to have their symptoms attributed to mental health issues. Dr. Gaffney’s statement, even if unintentional, resonated with this painful history of medical invalidation experienced by women with chronic illnesses.
The Imperative of Patient Self-Advocacy: In the face of diagnostic inertia and medical skepticism, patients with complex chronic illnesses often become their own experts. They research their symptoms, connect with peer communities, and bring potential diagnoses to their healthcare providers. While "self-diagnosis" is not a substitute for professional medical evaluation, it frequently serves as a vital first step in guiding patients toward appropriate specialists and eventual diagnoses. The experience shared by the original author, who took five years and multiple specialist visits (including two to the Mayo Clinic) to get an EDS diagnosis, only to be correctly guided by PNN readers, is a common narrative. This underscores the critical role of informed patients and peer support networks in navigating a challenging healthcare system.
Impact of Social Media on Medical Discourse: Platforms like X have become powerful, albeit double-edged, tools in medical discourse. They facilitate rapid information sharing, foster patient communities, and enable advocacy on an unprecedented scale. However, they also expose medical professionals to immediate public scrutiny and can amplify misunderstandings or perceived insensitivities. The incident with Dr. Gaffney serves as a stark reminder of the delicate balance between professional commentary and the lived experiences of patients, particularly when discussing sensitive topics like diagnostic accuracy for chronic conditions.
Diagnostic Challenges and Pain Management Policies: The past decade has seen significant restrictions on opioid prescribing, largely in response to the opioid crisis. While intended to curb addiction, these policies have had unintended consequences for patients with chronic pain. Many individuals with conditions like EDS, which cause persistent and severe pain, previously managed their symptoms with various medications, sometimes without a definitive, rare disease diagnosis. Now, the landscape has shifted; obtaining an official, recognized diagnosis has become increasingly crucial for accessing any form of comprehensive pain management, including non-opioid therapies and rehabilitative services, that might involve controlled substances. This creates an added pressure on both patients to seek definitive labels and on the medical system to provide them, highlighting the need for nuanced approaches to pain management that consider the complexities of chronic illness.
Implications for Medical Education and Trust:
The controversy surrounding Dr. Gaffney’s tweet underscores a critical need for enhanced medical education regarding complex, multi-systemic chronic illnesses. Many medical curricula still offer limited exposure to conditions like EDS, MCAS, and POTS, leading to a knowledge gap among general practitioners and even some specialists. Improving this education is paramount to reducing diagnostic delays, minimizing patient suffering, and fostering trust between patients and the medical community.
The incident also raises broader questions about the physician-patient relationship and the role of empathy in medical practice. When patients feel dismissed or invalidated, it erodes trust, potentially leading them to disengage from the healthcare system or seek alternative, sometimes unproven, treatments. For physicians, it prompts reflection on the impact of public statements and the responsibility to approach discussions about patient populations with sensitivity and a deep understanding of their lived experiences.
In conclusion, the debate ignited by Dr. Gaffney’s social media post serves as a powerful reminder of the ongoing challenges faced by patients with chronic, often invisible, illnesses. It highlights the pervasive issue of underdiagnosis, the persistent impact of gender bias in medicine, the vital role of patient advocacy, and the urgent need for improved medical education and empathetic communication within the healthcare system. Addressing these multifaceted issues requires an open dialogue, collaborative efforts between patients and providers, and a commitment to patient-centered care that prioritizes understanding and validating lived experiences.